2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.16 Racial Disparities in the Outcome of EGFRm NSCLC Patients

Pdf Summary

This study analyzed data from electronic medical records of patients with EGFR-mutant non-small cell lung cancer (NSCLC) between 2019 and 2023. The focus was on patients who were metastatic at diagnosis and received osimertinib as a first-line treatment. By examining racial disparities in outcomes, the researchers aimed to understand the influence of race on the efficacy of osimertinib in treating EGFR-mutant NSCLC.<br /><br />The patient cohort consisted of 149 individuals categorized by race into Black or African American (AA) (N=19), Asian (N=55), and White (N=75). Various statistical methods including Fisher’s exact test, Kruskal-Wallis test, Kaplan-Meier curves, and log-rank tests were employed to assess progression-free survival (PFS) among the different racial groups. Additionally, multivariable logistic regression models were used to analyze PFS exceeding 12 months.<br /><br />Significant findings indicated a numerical disadvantage in median PFS among Black and AA patients (12.9 months) compared to White (14.0 months) and Asian patients (17.8 months), though the differences were not statistically significant (p=0.52). Multivariable analysis highlighted that Asians had a statistically significant better PFS compared to Blacks or AAs (OR=3.36, 95% CI: 1.03-11.40, p=0.045).<br /><br />The study underscores the importance of addressing racial disparities to ensure equitable care and improve outcomes. Despite observing potential benefits of osimertinib across racial groups, further research with larger patient cohorts is needed. This should focus on identifying barriers, implementing targeted interventions, and promoting the inclusion of diverse populations in clinical trials to better understand and address these disparities. Such efforts are critical for developing optimized treatment strategies that cater to the diverse patient population suffering from EGFR-mutant NSCLC.

Asset Subtitle

Barliz Waissengrin

Keywords

EGFR-mutant NSCLC

osimertinib

racial disparities

progression-free survival

Kaplan-Meier curves

multivariable logistic regression

metastatic lung cancer

treatment efficacy

clinical trials

racial groups